Is Decision Diagnostics Stock a Good Investment?
Decision Diagnostics Investment Advice | DECN |
- Examine Decision Diagnostics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Decision Diagnostics' leadership team and their track record. Good management can help Decision Diagnostics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Technology space and any emerging trends that could impact Decision Diagnostics' business and its evolving consumer preferences.
- Compare Decision Diagnostics' performance and market position to its competitors. Analyze how Decision Diagnostics is positioned in terms of product offerings, innovation, and market share.
- Check if Decision Diagnostics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Decision Diagnostics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Decision Diagnostics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Decision Diagnostics is a good investment.
Not Rated
Examine Decision Diagnostics Stock
Researching Decision Diagnostics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.02. Decision Diagnostics had not issued any dividends in recent years. The entity had 1.1:1 split on the 28th of December 2011.
To determine if Decision Diagnostics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Decision Diagnostics' research are outlined below:
| Decision Diagnostics generated a negative expected return over the last 90 days | |
| Decision Diagnostics has some characteristics of a very speculative penny stock | |
| Decision Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| Decision Diagnostics currently holds 2.93 M in liabilities with Debt to Equity (D/E) ratio of 9.05, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Decision Diagnostics has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Decision Diagnostics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 1.98 M. Net Loss for the year was (29.67 M) with profit before overhead, payroll, taxes, and interest of 462.23 K. | |
| Decision Diagnostics currently holds about 210.85 K in cash with (1.4 M) of positive cash flow from operations. | |
| Decision Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Major Breakthrough Lucid Diagnostics Secures Game-Changing Insurance Coverage for Cancer Test - StockTitan |
Decision Diagnostics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 35.79 K.Market Cap |
|
Decision Diagnostics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (8.44) | (8.02) | |
| Return On Capital Employed | (2.61) | (2.48) | |
| Return On Assets | (4.72) | (4.49) | |
| Return On Equity | (70.55) | (67.03) |
Determining Decision Diagnostics' profitability involves analyzing its financial statements and using various financial metrics to determine if Decision Diagnostics is a good buy. For example, gross profit margin measures Decision Diagnostics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Decision Diagnostics' profitability and make more informed investment decisions.
Evaluate Decision Diagnostics' management efficiency
Decision Diagnostics has return on total asset (ROA) of (0.2122) % which means that it has lost $0.2122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (81.6052) %, meaning that it created substantial loss on money invested by shareholders. Decision Diagnostics' management efficiency ratios could be used to measure how well Decision Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of March 2025, Return On Tangible Assets is likely to grow to -8.02. In addition to that, Return On Capital Employed is likely to grow to -2.48. At this time, Decision Diagnostics' Other Current Assets are very stable compared to the past year. As of the 24th of March 2025, Total Current Assets is likely to grow to about 2.5 M, while Total Assets are likely to drop about 5.2 M.| Last Reported | Projected for Next Year | ||
| Tangible Book Value Per Share | (0.01) | (0.01) | |
| Enterprise Value Over EBITDA | (37.47) | (39.35) | |
| Price Book Value Ratio | 8.93 | 9.38 | |
| Enterprise Value Multiple | (37.47) | (39.35) | |
| Price Fair Value | 8.93 | 9.38 | |
| Enterprise Value | 6.4 M | 4 M |
Decision Diagnostics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta (1.83) |
Basic technical analysis of Decision Stock
Decision Diagnostics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Decision Diagnostics' Outstanding Corporate Bonds
Decision Diagnostics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Decision Diagnostics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Decision bonds can be classified according to their maturity, which is the date when Decision Diagnostics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Decision Stock media impact
Far too much social signal, news, headlines, and media speculation about Decision Diagnostics that are available to investors today. That information is available publicly through Decision media outlets and privately through word of mouth or via Decision internal channels. However, regardless of the origin, that massive amount of Decision data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Decision Diagnostics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Decision Diagnostics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Decision Diagnostics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Decision Diagnostics alpha.
Decision Diagnostics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Decision Diagnostics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
When determining whether Decision Diagnostics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Decision Diagnostics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Decision Diagnostics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Decision Diagnostics Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Decision Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Decision Stock, please use our How to Invest in Decision Diagnostics guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Decision Diagnostics. If investors know Decision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Decision Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.02) | Revenue Per Share | Quarterly Revenue Growth (0) | Return On Assets | Return On Equity |
The market value of Decision Diagnostics is measured differently than its book value, which is the value of Decision that is recorded on the company's balance sheet. Investors also form their own opinion of Decision Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Decision Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Decision Diagnostics' market value can be influenced by many factors that don't directly affect Decision Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Decision Diagnostics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Decision Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Decision Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.